Literature DB >> 10918348

The sensitivity to change over time of the Bristol Activities of Daily Living Scale in Alzheimer's disease.

L M Byrne1, P M Wilson, R S Bucks, A O Hughes, G K Wilcock.   

Abstract

Activities of daily living scales can be a useful tool in assessing change in people with dementia, either as the disease progresses or in response to treatment. However, little data exist as to the sensitivity to change of instruments used. The Bristol Activities of Daily Living Scale was developed with assistance from the carers of community dwelling people with dementia to be completed by such people and has been shown to have internal consistency as well as face and construct validity. This study aimed to analyse the sensitivity to change of the Bristol Activities of Daily Living Scale in people with Alzheimer's disease receiving anticholinesterase medication. Using the Clinician's Global Rating of Change as a gold standard for change, differences between Bristol Activities of Daily Living Scale scores before and after medication were compared with change in Mini-Mental State Examination, Alzheimer's Disease Assessment Scale - Cognitive and the Nurses Observation Scale for Geriatric Patients, in 61 older adults receiving anticholinesterase medication for Alzheimer's disease. Both the Bristol Activities of Daily Living Scale and the Nurses Observation Scale for Geriatric Patients are sensitive and specific in predicting improvement or stability as measured by the clinician's global rating of change. However, unlike the Nurses Observation Scale for Geriatric Patients, change over time in the Bristol Activities of Daily Living Scale significantly correlates with change in the Mini-Mental State Examination and the Alzheimer's Disease Assessment Scale - Cognitive. The Bristol Activities of Daily Living Scale is sensitive to change in activities of daily living and shows the expected and desirable relationship with measures of cognition. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10918348     DOI: 10.1002/1099-1166(200007)15:7<656::aid-gps163>3.0.co;2-q

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  16 in total

1.  Effectiveness of rivastigmine in Alzheimer's disease. Participation in trials should be based on clinical uncertainty, not enforcement.

Authors:  R Bullock; P Passmore; D Wilkinson; R Howard; R Jones
Journal:  BMJ       Date:  2000-02-19

2.  Improving access to dementia care: development and evaluation of a rural and remote memory clinic.

Authors:  Debra G Morgan; Margaret Crossley; Andrew Kirk; Carl D'Arcy; Norma Stewart; Jay Biem; Dorothy Forbes; Sheri Harder; Jenny Basran; Vanina Dal Bello-Haas; Lesley McBain
Journal:  Aging Ment Health       Date:  2009-01       Impact factor: 3.658

3.  Proxy completion of EQ-5D in patients with dementia.

Authors:  S Bryan; W Hardyman; P Bentham; A Buckley; A Laight
Journal:  Qual Life Res       Date:  2005-02       Impact factor: 4.147

Review 4.  Activities of daily living in patients with dementia: clinical relevance, methods of assessment and effects of treatment.

Authors:  Abhilash K Desai; George T Grossberg; Dharmesh N Sheth
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

5.  Follow-up for Alzheimer patients: European Alzheimer Disease Consortium position paper.

Authors:  F Nourhashémi; M G Olde Rikkert; A Burns; B Winblad; G B Frisoni; J Fitten; B Vellas
Journal:  J Nutr Health Aging       Date:  2010-02       Impact factor: 4.075

6.  A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease.

Authors:  Gordon Wilcock; Ian Howe; Hilary Coles; Sean Lilienfeld; Luc Truyen; Young Zhu; Roger Bullock; Paul Kershaw
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

7.  Individual Cognitive Stimulation Therapy for dementia (iCST): study protocol for a randomized controlled trial.

Authors:  Martin Orrell; Lauren A Yates; Alistair Burns; Ian Russell; Robert T Woods; Zoe Hoare; Esme Moniz-Cook; Catherine Henderson; Martin Knapp; Aimee Spector; Vasiliki Orgeta
Journal:  Trials       Date:  2012-09-22       Impact factor: 2.279

8.  A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial).

Authors:  Clive Ballard; Marisa Margallo Lana; Megan Theodoulou; Simon Douglas; Rupert McShane; Robin Jacoby; Katja Kossakowski; Ly-Mee Yu; Edmund Juszczak
Journal:  PLoS Med       Date:  2008-04-01       Impact factor: 11.069

9.  Validation of the dementia care assessment packet-instrumental activities of daily living.

Authors:  Seok Bum Lee; Jeong Ran Park; Jeong-Hwa Yoo; Joon Hyuk Park; Jung Jae Lee; Jong Chul Yoon; Jin Hyeong Jhoo; Dong Young Lee; Jong Inn Woo; Ji Won Han; Yoonseok Huh; Tae Hui Kim; Ki Woong Kim
Journal:  Psychiatry Investig       Date:  2013-09-16       Impact factor: 2.505

10.  Community occupational therapy for people with dementia and family carers (COTiD-UK) versus treatment as usual (Valuing Active Life in Dementia [VALID] programme): study protocol for a randomised controlled trial.

Authors:  Jennifer Wenborn; Sinéad Hynes; Esme Moniz-Cook; Gail Mountain; Fiona Poland; Michael King; Rumana Omar; Steven Morris; Myrra Vernooij-Dassen; David Challis; Susan Michie; Ian Russell; Catherine Sackley; Maud Graff; Aidan O'Keeffe; Nadia Crellin; Martin Orrell
Journal:  Trials       Date:  2016-02-03       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.